Recombinant IgA Antibodies

The production of monoclonal antibodies and the development of recombinant antibody technology have made antibodies one of the largest classes of drugs in development for prophylactic, therapeutic and diagnostic purposes. Currently, all of the Food and Drug Administration (FDA)- approved antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Esther M., Chintalacharuvu, Koteswara R., Morrison, Sherie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2007
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121033/
http://dx.doi.org/10.1007/978-0-387-72232-0_15
_version_ 1783515109543378944
author Yoo, Esther M.
Chintalacharuvu, Koteswara R.
Morrison, Sherie L.
author_facet Yoo, Esther M.
Chintalacharuvu, Koteswara R.
Morrison, Sherie L.
author_sort Yoo, Esther M.
collection PubMed
description The production of monoclonal antibodies and the development of recombinant antibody technology have made antibodies one of the largest classes of drugs in development for prophylactic, therapeutic and diagnostic purposes. Currently, all of the Food and Drug Administration (FDA)- approved antibodies are immunoglobulin Gs (IgGs). However, more than 95%of the infections are initiated at the mucosal surfaces, where IgA is the primary immune effector antibody.
format Online
Article
Text
id pubmed-7121033
institution National Center for Biotechnology Information
language English
publishDate 2007
record_format MEDLINE/PubMed
spelling pubmed-71210332020-04-06 Recombinant IgA Antibodies Yoo, Esther M. Chintalacharuvu, Koteswara R. Morrison, Sherie L. Mucosal Immune Defense: Immunoglobulin A Article The production of monoclonal antibodies and the development of recombinant antibody technology have made antibodies one of the largest classes of drugs in development for prophylactic, therapeutic and diagnostic purposes. Currently, all of the Food and Drug Administration (FDA)- approved antibodies are immunoglobulin Gs (IgGs). However, more than 95%of the infections are initiated at the mucosal surfaces, where IgA is the primary immune effector antibody. 2007 /pmc/articles/PMC7121033/ http://dx.doi.org/10.1007/978-0-387-72232-0_15 Text en © Springer Science+Business Media, LLC 2007 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Yoo, Esther M.
Chintalacharuvu, Koteswara R.
Morrison, Sherie L.
Recombinant IgA Antibodies
title Recombinant IgA Antibodies
title_full Recombinant IgA Antibodies
title_fullStr Recombinant IgA Antibodies
title_full_unstemmed Recombinant IgA Antibodies
title_short Recombinant IgA Antibodies
title_sort recombinant iga antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121033/
http://dx.doi.org/10.1007/978-0-387-72232-0_15
work_keys_str_mv AT yooestherm recombinantigaantibodies
AT chintalacharuvukoteswarar recombinantigaantibodies
AT morrisonsheriel recombinantigaantibodies

Ejemplares similares